Neurocrine Biosciences, Inc. (NBIX) Stock

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

Neurocrine Biosciences, Inc. is led by CEO Kyle W. Gano, employs 2,000 people, headquartered in San Diego, US, publicly traded since 1996.

Neurocrine Biosciences, Inc. (NBIX) stock trades at $182.83 with a market capitalization of $18.38B. The stock is valued at a price-to-earnings (P/E) ratio of 23.97, price-to-book of 4.79, price-to-sales of 5.13. Over the past 52 weeks the stock has ranged between $122.14 and $182.83, and currently trades at its 52-week high.

On profitability, Neurocrine Biosciences, Inc. generates a return on equity (ROE) of 22.50% — well above the market average, a sign of a high-quality business, return on capital employed of 19.02%, an operating margin of 25.19%, a net profit margin of 21.55%.

In its most recent fiscal year, Neurocrine Biosciences, Inc. reported annual revenue of $2.9B, net profit of $479.0M, revenue has compounded at 22.3% a year over the last five years, profit at 3.3% a year.

The balance sheet shows a debt-to-equity ratio of 0.12 — a conservative balance sheet with little leverage risk, a current ratio of 3.40, total assets of $4.6B, $713.0M in cash and equivalents.

NBIX has an average daily trading volume of 1,200,000 shares, a beta of 0.40 (less volatile than the overall market).

Official website: www.neurocrine.com